Nasal spray for the treatment of fluid in the middle ear

Otifex Therapeutics is developing a new nasal spray product for the treatment of fluid in the middle ear, the most common cause of acquired hearing loss in childhood, with the aim to reduce the need for grommet operations. Funding from Commercialisation Australia will help support an experienced executive to manage the necessary clinical trials and further develop the commercialisation strategy.